FrancophonIA/ELRC3.0 huggingface dataset:
English: Other information about Bydureon
Estonian: Muu teave Bydureoni kohta
English: What is Bydureon and what is it used for?
Estonian: Mis on Bydureon ja milleks seda kasutatakse?
English: Bydureon exenatide
Estonian: Bydureon eksenatiid
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bydureon have been included in the summary of product characteristics and the package leaflet.
Estonian: Bydureoni ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: This leads to excess glucose in the blood.
Estonian: See põhjustab vere liigse glükoosisisalduse.
English: The European Medicines Agency noted that the benefits of Bydureon, such as its effect on reducing the levels of HbA1c, compare well with those of comparator medicines and that its side effects are manageable.
Estonian: Euroopa Ravimiamet (EMA) märkis, et Bydureoni kasulikkus, näiteks HbA1c-sisalduse vähendamisel, on võrdlusravimitega võrreldav ja kõrvalnähud on hallatavad.
English: Prolonged-release means that the active substance is released slowly after being injected.
Estonian: Toimeaine prolongeeritud (pikaajaline) vabastamine tähendab, et pärast süstimist vabaneb toimeaine aeglaselt.
English: This helps to control blood glucose levels.
Estonian: See aitab vere glükoosisisaldust reguleerida.
English: Bydureon is a diabetes medicine used together with other diabetes medicines including long-acting insulin to treat adults with type 2 diabetes whose blood glucose (sugar) levels are not adequately controlled with the other medicines.
Estonian: Bydureon on diabeediravim, mida kasutatakse koos teiste diabeediravimitega, sh pika toimeajaga insuliiniga, et ravida II tüüpi diabeediga (suhkurtõvega) täiskasvanuid, kellel ei saa vere glükoosisisaldust (suhkrusisaldust) teiste ravimitega piisavalt reguleerida.
English: Bydureon is given by injection under the skin once a week on the same day each week in the abdomen (belly), thigh or back of the upper arm.
Estonian: Bydureoni manustatakse kord nädalas, alati samal nädalapäeval subkutaanse (nahaaluse) süstega kõhtu, reide või õlavarre tagaküljele.
English: It is not intended to provide practical advice on how to use Bydureon.
Estonian: Hindamisaruandes ei anta Bydureoni kasutamise praktilisi nõuandeid.
English: Bydureon contains the active substance exenatide.
Estonian: Bydureon sisaldab toimeainena eksenatiidi.
English: Why is Bydureon approved?
Estonian: Miks Bydureon heaks kiideti?
English: In addition, reactions at the site of injection (itching and redness), low blood sugar levels (when used with a sulphonylurea) and headache occur.
Estonian: Samuti esinevad süstekoha reaktsioonid (sügelus ja punetus), vere glükoosisisalduse vähenemine (kasutamisel koos sulfonüüluurearavimiga) ja peavalu.
English: When adding Bydureon to a sulphonylurea, the doctor may need to reduce the dose of the sulphonylurea because there is a risk of hypoglycaemia (low blood sugar levels).
Estonian: Kui Bydureoni manustatakse koos sulfonüüluurearavimiga, võib arst vähendada sulfonüüluurearavimi annust, et vähendada hüpoglükeemia (vere liiga väike glükoosisisaldus) riski.
English: In all of the studies, the main measure of effectiveness was the reduction in the amount of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
Estonian: Kõigis uuringutes oli efektiivsuse põhinäitaja vere glükoosisisalduse reguleeritavust näitava aine glükohemoglobiini (HbA1c) sisalduse vähenemine veres.
English: For practical information about using Bydureon, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Bydureoni kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For the full list of side effects and restrictions with Bydureon, see the package leaflet.
Estonian: Bydureoni kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: What are the risks associated with Bydureon?
Estonian: Mis riskid Bydureoniga kaasnevad?
English: Patients inject themselves using a kit supplied with the medicine.
Estonian: Patsiendid süstivad endale ravimit spetsiaalse komplekti abil ise.
English: The first two studies (in a total of 555 patients) compared Bydureon with another medicine also containing exenatide but given twice daily, both given as add-on treatment to oral diabetes medicines or diet and exercise alone.
Estonian: Esimeses kahes uuringus (kokku 555 patsienti) võrreldi Bydureoni teise ravimiga, mis sisaldas samuti eksenatiidi, kuid mida manustati kaks korda ööpäevas; mõlemat ravimit manustati suukaudsete diabeediravimite või ainult dieedi ja kehalise koormuse lisaravina.
English: For more information about treatment with Bydureon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Bydureoniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The most common side effects with Bydureon are nausea (feeling sick) and diarrhoea.
Estonian: Bydureoni kõige sagedamad kõrvalnähud on iiveldus ja kõhulahtisus.
English: How is Bydureon used?
Estonian: Kuidas Bydureoni kasutatakse?
English: How does Bydureon work?
Estonian: Kuidas Bydureon toimib?
English: What benefits of Bydureon have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Bydureoni kasulikkus?
English: In the sixth study (in 464 patients), Bydureon given together with insulin glargine with or without metformin was compared with placebo (dummy treatment) also given with insulin glargine with or without metformin.
Estonian: Kuuendas uuringus (464 patsienti) võrreldi Bydureoni ja glargiininsuliini (koos metformiiniga või ilma) kasutamist platseeboga (näiv ravim), mida anti samuti koos glargiininsuliiniga (koos metformiiniga või ilma).
English: In the fifth study (in 695 patients), Bydureon given with dapagliflozin was compared with Bydureon alone and dapagliflozin alone.
Estonian: Viiendas uuringus (695 patsienti) võrreldi Bydureoni ja dapagliflosiini koos kasutamist Bydureoni ja dapagliflosiini kasutamisega ainuravimitena.
English: Bydureon is available as a powder and solvent that are mixed together to make a prolonged-release suspension for injection providing 2 mg of exenatide.
Estonian: Bydureoni turustatakse 2 mg eksenatiidi prolongeeritult vabastava süstesuspensiooni pulbri ja lahustina.
English: In the first study, Bydureon reduced HbA1c levels by an average of 1.9 percentage points after 30 weeks of treatment, compared with an average reduction of 1.5 points with exenatide given twice daily.
Estonian: Esimeses uuringus vähendas Bydureon HbA1c-sisaldust pärast 30-nädalast ravi keskmiselt 1,9% võrra, kaks korda ööpäevas manustatav eksenatiid keskmiselt 1,5% võrra.
English: The third study (in 514 patients) compared Bydureon with sitagliptin or pioglitazone as add-on treatment to metformin.
Estonian: Kolmandas uuringus (514 patsienti) võrreldi Bydureoni sitagliptiini või pioglitasooniga metformiini lisaravina.
English: This means that it acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin released by the pancreas in response to food.
Estonian: Bydureoni toimeaine eksenatiid on inkretinomimeetikum ehk aine, mis toimib sarnaselt sooles tekkivate hormoonide inkretiinidega, suurendades toidu mõjul kõhunäärme eritatava insuliini kogust.
English: The average reduction with Bydureon plus dapagliflozin was 2.0 points after 28 weeks, compared with an average reduction of 1.6 points with Bydureon alone and 1.4 points with dapagliflozin alone.
Estonian: Bydureoni ja dapagliflosiini kombinatsioon vähendas HbA1c-sisaldust 28-nädalase ravi järel keskmiselt 2,0% võrra, Bydureon ainuravimina keskmiselt 1,6% võrra ja dapagliflosiin ainuravimina keskmiselt 1,4% võrra.
English: The fourth study (in 456 patients) compared Bydureon with insulin glargine (a long-acting insulin) as add-on treatment to metformin with or without a sulphonylurea.
Estonian: Neljandas uuringus (456 patsienti) võrreldi Bydureoni glargiininsuliiniga (pika toimeajaga insuliin) ainult metformiini või metformiini ja sulfonüüluurearavimi kombinatsiooni lisaravina.
English: Bydureon reduced HbA1c levels by an average of 1.4 points after 26 weeks of treatment, compared with an average reduction of 0.8 and 1.1 points with sitagliptin and pioglitazone respectively.
Estonian: Bydureon vähendas HbA1c-sisaldust 26-nädalase ravi järel keskmiselt 1,4% võrra, sitagliptiin keskmiselt 0,8% võrra ja pioglitasoon keskmiselt 1,1% võrra.
English: At the start of the study, the patients' HbA1c levels were around 9.3%.
Estonian: Uuringu algul oli patsientide keskmine HbA1c-sisaldus ligikaudu 9,3%.
English: In the second study, the average reduction was 1.6 points after 24 weeks of treatment with Bydureon, compared with an average reduction of 0.9 points with exenatide given twice daily.
Estonian: Teises uuringus vähendas Bydureon HbA1c-sisaldust pärast 24-nädalast ravi keskmiselt 1,6% võrra ja kaks korda ööpäevas manustatav eksenatiid keskmiselt 0,9% võrra.
English: The average reduction with Bydureon was 1.5 points after 26 weeks, compared with an average reduction of 1.3 points with insulin glargine.
Estonian: Bydureon vähendas HbA1c-sisaldust 26-nädalase ravi järel keskmiselt 1,5% võrra ja glargiininsuliin 1,3% võrra.
English: At the start of the studies, the patients' HbA1c levels were around 8.4%.
Estonian: Uuringute algul oli patsientide keskmine HbA1c-sisaldus ligikaudu 8,4%.
English: At the start of the study, the patients' HbA1c levels were around 8.5%.
Estonian: Uuringu algul oli patsientide keskmine HbA1c-sisaldus ligikaudu 8,5%.
English: The average reduction with Bydureon was 1.0 point after 28 weeks, compared with an average reduction of 0.2 points with placebo.
Estonian: Bydureon vähendas HbA1c-sisaldust 28-nädalase ravi järel keskmiselt 1,0% võrra ja platseebo 0,2% võrra.
English: At the start of the study, the patients' HbA1c levels were around 8.3%.
Estonian: Uuringu algul oli patsientide keskmine HbA1c-sisaldus ligikaudu 8,3%.
English: The most important serious side effects are serious infections.
Estonian: Kõige olulisemad rasked kõrvalnähud on rasked infektsioonid.
English: However, these side effects are considered manageable.
Estonian: Neid kõrvalnähte peetakse siiski hallatavaks.
English: Further information on Rinvoq can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rinvoq.
Estonian: Lisateave Rinvoqi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/rinvoq.
English: What measures are being taken to ensure the safe and effective use of Rinvoq?
Estonian: Mis meetmed võetakse, et tagada Rinvoqi ohutu ja efektiivne kasutamine?
English: Rinvoq (upadacitinib)
Estonian: Rinvoq (upadatsitiniib)
English: The European Medicines Agency therefore decided that Rinvoq's benefits are greater than its risks and that it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Rinvoqi kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: These studies involved rating disease activity in 28 joints in the body on a standard scale.
Estonian: Nendes uuringutes hinnati haiguse aktiivsust organismi 28 liigeses standardskaalal.
English: Studies found that it reduced disease activity when used alone or combined with other medicines.
Estonian: Uuringutes leiti, et ravim vähendas eraldi või koos teiste ravimitega kasutamisel haiguse aktiivsust.
English: The recommended dose of Rinvoq is one tablet once a day.
Estonian: Rinvoqi soovitatav annus on üks tablett üks kord ööpäevas.
English: As for all medicines, data on the use of Rinvoq are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Rinvoqi kasutamise kohta pidevat järelevalvet.
English: The patients were being treated with conventional disease-modifying anti-rheumatic medicines (chloroquine, hydroxychloroquine, leflunomide or sulfasalazine, often combined with methotrexate).
Estonian: Patsiente raviti tavapäraste haigust modifitseerivate reumavastaste ravimitega (klorokiin, hüdroksüklorokiin, leflunomiid või sulfasalasiin, sageli koos metotreksaadiga).
English: Other information about Rinvoq
Estonian: Muu teave Rinvoqi kohta
English: The most common side effects with Rinvoq (which may affect more than 1 in 10 people) are upper respiratory tract infections (nose and throat infections).
Estonian: Rinvoqi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on ülemiste hingamisteede (nina ja neelu) infektsioonid.
English: For more information about using Rinvoq, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Rinvoqi kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Rinvoq must not be used in patients with tuberculosis or serious infections.
Estonian: Rinvoqit ei tohi kasutada tuberkuloosi või raskete infektsioonidega patsiendid.
English: What is Rinvoq and what is it used for?
Estonian: Mis on Rinvoq ja milleks seda kasutatakse?
English: Side effects reported with Rinvoq are carefully evaluated and any necessary action taken to protect patients.
Estonian: Rinvoqi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rinvoq have also been included in the summary of product characteristics and the package leaflet.
Estonian: Rinvoqi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: It is available as 15 mg tablets.
Estonian: Rinvoqit turustatakse 15 mg tablettidena.
English: These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.
Estonian: Need ensüümid osalevad põletikku põhjustavate protsesside käivitamises ja nende toime blokeerimine vähendab põletikku liigestes.
English: The company will also supply a patient alert card describing warning signs of Rinvoq's serious side effects and how to get help, and a reminder not to use it during pregnancy.
Estonian: Ettevõte koostab ka patsiendi hoiatuskaardi, milles kirjeldatakse Rinvoqi raskete kõrvalnähtude ilmnemist ja vajalikku abi, ning meeldetuletuse, et ravimit ei tohi kasutada raseduse ajal.
English: Why is Rinvoq authorised in the EU?
Estonian: Miks Rinvoq ELis heaks kiideti?
English: Treatment with the medicine should be started and supervised by a doctor experienced in diagnosing and treating rheumatoid arthritis.
Estonian: Ravi Rinvoqiga peab alustama ja jälgima reumatoidartriidi diagnoosimises ja ravis kogenud arst.
English: Rinvoq is used for moderate or severe rheumatoid arthritis that cannot be controlled well enough with disease-modifying anti-rheumatic medicines or if the patient cannot take these medicines.
Estonian: Rinvoqit kasutatakse mõõduka või raske reumatoidartriidi korral, mida ei saa piisavalt hästi ohjata haigust modifitseerivate reumaatiliste ravimitega või kui patsient ei saa neid ravimeid võtta.
English: Five studies involving a total of nearly 4,400 patients found Rinvoq effective in reducing symptoms in patients with moderate to severe rheumatoid arthritis.
Estonian: Viies uuringus, milles osales kokku ligi 4400 patsienti, leiti, et Rinvoq on mõõduka kuni raske reumatoidartriidiga patsientide sümptomite vähendamisel efektiivne.
English: The fifth study involved patients for whom a biological disease-modifying anti-rheumatic medicine was either not suitable or did not work well enough.
Estonian: Viiendas uuringus osalesid patsiendid, kellele bioloogilist haigust modifitseeriv reumavastane ravim kas ei sobinud või ei toiminud piisavalt hästi.
English: What are the risks associated with Rinvoq?
Estonian: Mis riskid Rinvoqiga kaasnevad?
English: The first study was in patients who had not previously been treated with methotrexate.
Estonian: Esimeses uuringus osalesid patsiendid, keda ei olnud varem metotreksaadiga ravitud.
English: Patients treated with Rinvoq may have side effects that include infection, neutropenia (low count of a type of white blood cell), and blood tests that suggest liver or muscle damage and raised blood lipids.
Estonian: Rinvoqiga ravitud patsientidel võivad tekkida kõrvalnähud, sealhulgas infektsioon, neutropeenia (teatud valgeliblede vähesus) ja vereanalüüside hälbed, mis viitavad maksa- või lihasekahjustustele ja vere suurenenud lipiidisisaldusele.
English: Rinvoq was effective at controlling moderate to severe rheumatoid arthritis in patients whose disease had not improved enough with other disease-modifying anti-rheumatic medicines.
Estonian: Rinvoq oli efektiivne mõõduka kuni raske reumatoidartriidi ohjamises patsientidel, kelle haigus ei olnud teiste haigust modifitseerivate reumavastaste ravimitega piisavalt leevenenud.
English: It can be used on its own or with methotrexate, another medicine for rheumatoid arthritis.
Estonian: Seda tohib kasutada ainuravimina või koos metotreksaadiga (samuti reumatoidartriidi ravim).
English: The company that markets Rinvoq will provide information to healthcare professionals about the risks of infection, harm to the unborn baby if Rinvoq is taken during pregnancy, and problems affecting the heart and circulation.
Estonian: Rinvoqi turustaja annab tervishoiutöötajatele teabe infektsiooniriskide, Rinvoqi rasedusaegse kasutamise lootekahjustuse riski ning südame- ja vereringeprobleemide kohta.
English: For the full list of side effects of Rinvoq, see the package leaflet.
Estonian: Rinvoqi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The doctor may interrupt treatment in case of certain side effects, including falls in blood cell counts.
Estonian: Teatud kõrvalnähtude, sealhulgas vererakkude sisalduse vähenemise korral võib arst ravi katkestada.
English: In patients with rheumatoid arthritis, the immune system (the body's defences) attacks healthy tissue, causing inflammation in the joints.
Estonian: Reumatoidartriidiga patsientidel ründab immuunsüsteem (organismi kaitsemehhanismid) terveid kudesid, põhjustades liigesepõletikku.
English: The second study was in patients whose disease was not well controlled with disease-modifying antirheumatic medicines.
Estonian: Teises uuringus osalesid patsiendid, kelle haigus ei olnud haigust modifitseerivate reumavastaste ravimitega hästi ohjatud.
English: How is Rinvoq used?
Estonian: Kuidas Rinvoqit kasutatakse?
English: Upadacitinib works by blocking the action of enzymes called Janus kinases.
Estonian: Upadatsitiniib blokeerib Janus-kinaaside (teatud ensüümid) toime.
English: How does Rinvoq work?
Estonian: Kuidas Rinvoq toimib?
English: What benefits of Rinvoq have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Rinvoqi kasulikkus?
English: Rinvoq contains the active substance upadacitinib.
Estonian: Rinvoq sisaldab toimeainena upadatsitiniibi.
English: An overview of Rinvoq and why it is authorised in the EU
Estonian: Ülevaade ravimist Rinvoq ja ELis müügiloa väljastamise põhjendus
English: The fourth study was also in patients whose disease was not controlled well enough with methotrexate.
Estonian: Neljandas uuringus osalesid samuti patsiendid, kelle haigust metotreksaat ei ohjanud piisavalt.
English: It must also not be used in patients with severe liver problems or during pregnancy.
Estonian: Rinvoqit ei tohi kasutada raskete maksaprobleemidega ega rasedad patsiendid.
English: Rinvoq can only be obtained with a prescription.
Estonian: Rinvoq on retseptiravim.
English: It found that 45% of patients treated with methotrexate plus Rinvoq had low disease activity after 12 weeks compared with 29% of patients treated with methotrexate plus adalimumab (a biological diseasemodifying anti-rheumatic medicine) and 14% of patients receiving methotrexate plus placebo.
Estonian: Leiti, et pärast 12 nädalat oli haiguse väikese aktiivsusega patsiente 45% metotreksaati ja Rinvoqit kasutanutest, 29% metotreksaati ja adalimumaabi kasutanutest (bioloogiline haigust modifitseeriv reumavastane ravim) ning 14% metotreksaati ja platseebot saanud patsientidest.
English: It found that after 24 weeks, 48% of patients were in remission (clear of symptoms) after treatment with Rinvoq compared with 19% of patients receiving methotrexate.
Estonian: Leiti, et pärast 24 nädalat oli remissioonis (sümptomiteta) 48% Rinvoqit ja 19% metotreksaati saanud patsientidest.
English: Rinvoq is a medicine for treating adults with rheumatoid arthritis, a disease that causes inflammation of the joints.
Estonian: Rinvoq on ravim, mida kasutatakse mõõduka kuni raske reumatoidartriidiga (liigesepõletikku põhjustav haigus) täiskasvanute raviks.
English: Of the patients who also received Rinvoq, 43% had low disease activity compared with 14% of patients receiving placebo.
Estonian: Haiguse väikese aktiivsusega patsiente oli Rinvoqit kasutanute seas 43% ja platseeborühmas 14%.
English: The third study was in patients whose disease was not controlled well with methotrexate.
Estonian: Kolmandas uuringus osalesid patsiendid, kelle haigust metotreksaat ei ohjanud piisavalt.
English: It found that of patients treated with Rinvoq, 48% had low disease activity after 12 weeks compared with 17% of patients receiving placebo (a dummy treatment).
Estonian: Leiti, et pärast 12 nädalat oli haiguse väikese aktiivsusega patsiente 48% Rinvoqit ja 17% platseebot (näiv ravim) saanud patsientidest.
English: It found that 45% of the patients treated with Rinvoq on its own had low disease activity after 14 weeks compared with 19% of patients continuing their methotrexate treatment.
Estonian: Leiti, et pärast 14 nädalat oli haiguse väikese aktiivsusega patsiente ainult Rinvoqit kasutanutest 45% ja metotreksaatravi jätkanutest 19%.
English: Upadacitinib, the active substance in Rinvoq, is an immunosuppressant.
Estonian: Rinvoqi toimeaine upadatsitiniib on immunosupressant ehk aine, mis vähendab immuunsüsteemi aktiivsust.
English: Unopened: 3 years.
Estonian: Avamata: 3 aastat.
English: After opening, use within 90 days.
Estonian: Pärast avamist kasutada ära 90 päeva jooksul.
English: Infection, including bacterial infection
Estonian: infektsioon, kaasa arvatud bakteriaalne infektsioon
English: It is important that you consult your doctor, who will tell you what to do.
Estonian: On oluline, et peaksite nõu oma arstiga, kes ütleb teile, mida teha.
English: • CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Estonian: • TINGIMUSED VÕI PIIRANGUD, MIS PUUDUTAVAD RAVIMI OHUTUT JA EFEKTIIVSET KASUTAMIST
English: The medicinal product was not genotoxic.
Estonian: Ravim ei olnud genotoksiline.
English: Gel, 60 g
Estonian: Geel, 60 g
English: • Women planning a pregnancy.
Estonian: • rasedust planeerivad naised.
English: Sometimes it is necessary to interrupt treatment, your doctor will inform you about this.
Estonian: Mõnikord on vajalik ravi katkestada ja teie arst annab teile selle kohta teavet.
English: - Panretin contains alcohol.
Estonian: - Panretin sisaldab alkoholi.
English: No action required except continued monitoring.
Estonian: Vaja ei ole teha muud, kui jätkata jälgimist.
English: Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Estonian: Teatage oma arstile, kui te kasutate või olete hiljuti kasutanud mis tahes muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimid.
English: There are no specific recommendations for use in elderly men (above 65 years of age).
Estonian: Erisoovitusi kasutamisel eakatel meestel (üle 65-aastastel) ei ole.
English: • Do not stop treatment at the first sign of improvement.
Estonian: • Ärge katkestage ravi esimeste paranemisemärkide ilmnemisel.
English: Study 2 (BD)
Estonian: 2. uuring (BD)